. . . . . . . . . . . "Sevoflurano"@en . . "Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca²⁺ activated potassium channel, the glutamate receptor, and the glycine receptor."@en . . . "Sevoflurane"@en . . . . . . . . . "Humans and other mammals"@en . . "Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia]"@en . . . . . . "Ross C. Terrell, \"Method for the preparation of sevoflurane.\" U.S. Patent US5969193, issued December, 1979."@en . . . . . "28523-86-6"@en . . . . . . . . . "15-23 hours"@en . . . "Sevoflurane"@en . "Sevofluran"@en . . "1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane"@en . "Sevofluranum"@en . "LC₅₀=49881 ppm/hr (rat), LD₅₀=10.8 g/kg (rat)"@en . "Rapidly absorbed into circulation via the lungs, however solubility in the blood is low."@en . . "approved"@en . . . . . . "Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery."@en . . " "@en . . . . . . . . . . . . "The low solubility of sevoflurane facilitates rapid elimination via the lungs. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride."@en .